1. Home
  2. MRVI vs FFA Comparison

MRVI vs FFA Comparison

Compare MRVI & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • FFA
  • Stock Information
  • Founded
  • MRVI 2014
  • FFA 2004
  • Country
  • MRVI United States
  • FFA United States
  • Employees
  • MRVI N/A
  • FFA N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • FFA Investment Managers
  • Sector
  • MRVI Health Care
  • FFA Finance
  • Exchange
  • MRVI Nasdaq
  • FFA Nasdaq
  • Market Cap
  • MRVI 376.2M
  • FFA 416.1M
  • IPO Year
  • MRVI 2020
  • FFA N/A
  • Fundamental
  • Price
  • MRVI $3.24
  • FFA $21.83
  • Analyst Decision
  • MRVI Hold
  • FFA
  • Analyst Count
  • MRVI 9
  • FFA 0
  • Target Price
  • MRVI $4.54
  • FFA N/A
  • AVG Volume (30 Days)
  • MRVI 1.7M
  • FFA 26.1K
  • Earning Date
  • MRVI 11-06-2025
  • FFA 01-01-0001
  • Dividend Yield
  • MRVI N/A
  • FFA 6.72%
  • EPS Growth
  • MRVI N/A
  • FFA N/A
  • EPS
  • MRVI N/A
  • FFA N/A
  • Revenue
  • MRVI $219,830,000.00
  • FFA N/A
  • Revenue This Year
  • MRVI N/A
  • FFA N/A
  • Revenue Next Year
  • MRVI $7.27
  • FFA N/A
  • P/E Ratio
  • MRVI N/A
  • FFA N/A
  • Revenue Growth
  • MRVI N/A
  • FFA N/A
  • 52 Week Low
  • MRVI $1.67
  • FFA $15.84
  • 52 Week High
  • MRVI $8.29
  • FFA $19.30
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 50.18
  • FFA 60.93
  • Support Level
  • MRVI $3.32
  • FFA $21.28
  • Resistance Level
  • MRVI $3.55
  • FFA $21.58
  • Average True Range (ATR)
  • MRVI 0.19
  • FFA 0.24
  • MACD
  • MRVI -0.04
  • FFA 0.02
  • Stochastic Oscillator
  • MRVI 8.82
  • FFA 92.94

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About FFA First Trust Enhanced Equity Income Fund

First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.

Share on Social Networks: